Amneal Pharmaceuticals, Inc. (AMRX) is among the best performing pharma stocks in 2025, with Truist raising its price target to $15 from $14 on January 7. The company recently received FDA approval for two biosimilars, Boncresa™ and Oziltus™, in partnership with mAbxience. This expands their portfolio to five commercial biosimilars, enhancing their position in the Affordable Medicines segment. Amneal Pharmaceuticals operates in the generics, specialty, and AvKARE segments, offering a diverse product portfolio. While AMRX shows promise, there are other AI stocks with greater potential for investment.

Read more at Yahoo Finance: Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14